Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Dose Confirmation Study of FLT180a (Adeno-associated Viral Vector Containing the Padua Variant of a Codon-optimized Human Factor IX Gene) in Adult Subjects With Hemophilia B

NCT05164471 is registered in ClinicalTrials.gov with Spur Therapeutics as lead sponsor.

NCT NCT05164471
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05164471 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Dose Confirmation Study of FLT180a (Adeno-associated Viral Vector Containing the Padua Variant of a Codon-optimized Human Factor IX Gene) in Adult Subjects With Hemophilia B
Lead sponsor
Spur Therapeutics
Phase
Phase 1/2
Overall status
Terminated
Start date
December 6, 2021
Completion date
May 31, 2023
Enrollment
6 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

hemophilia b